Cladis Investment Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Cladis Investment Advisory's VRTX Position: Q2 2026 in Review
Cladis Investment Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 3.1% in Q2 2026, buying an estimated $7.53K and bringing the position to 559 shares worth $278K. The position accounts for 0.13% of the portfolio, ranked #140.
Cladis Investment Advisory first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Cladis Investment Advisory held 559 shares of Vertex Pharmaceuticals worth $278K as of Q2 2026.
- Cladis Investment Advisory bought 17 Vertex Pharmaceuticals shares in Q2 2026, an estimated $7.53K.
- Vertex Pharmaceuticals made up 0.13% of Cladis Investment Advisory's portfolio in Q2 2026, its #140 holding.
- Cladis Investment Advisory first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Cladis Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.